title: Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I.
abstract: In recent classifications of gastric endocrine tumors, tumors arising in patients with multiple endocrine neoplasia type 1 (MEN-1) are regarded to be regulated by the concomitant hypergastrinemia resulting from to pancreatic or, most commonly, duodenal gastrinomas and to have a benign behavior. In this article, we report on two cases of MEN-1 gastric neuroendocrine tumors having a fatal course. Case 1 was a young male with hyperparathyroidism and Zollinger-Ellison syndrome and with florid development of multiple gastric carcinoids and multiple duodenal gastrinomas. Metastases occurred in the liver, of exclusive gastric origin, in periduodenal lymph nodes, of exclusive duodenal origin, and in perigastric lymph nodes, of mixed origin. The patient died 48 months after diagnosis. Case 2 was an adult female patient with hyperparathyroidism, adrenocortical disorders, and gastric tumors but no hypergastrinemia. The patient died 3 months after tumor diagnosis. At autopsy, the stomach showed multiple benign carcinoids and two independent neuroendocrine carcinomas not reported before in MEN-1 and massively metastatizing to lymph nodes, liver, and peritoneum. Multiple islet cell tumors mostly producing pancreatic polypeptide were found, whereas gastrinomas were seen in neither the pancreas nor the duodenum. Allelic losses at the MEN-1 gene locus in chromosome 11q13, the mechanism responsible for tumor development in MEN-1 syndrome, were demonstrated in the carcinoid tumors of case 1 and in the neuroendocrine carcinoma of case 2. We conclude that gastric neuroendocrine tumors in patients with MEN-1 may have a poor outcome, they have the same genetic mechanism as MEN-1 tumors in other organs, and they may be independent of the trophic effect of hypergastrinemia.
authors.affiliation: Institute of Anatomic Pathology, University of Parma, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Bordi
authors.forename: A
authors.initials: A
authors.lastname: Falchetti
authors.forename: C
authors.initials: C
authors.lastname: Azzoni
authors.forename: T
authors.initials: T
authors.lastname: D'Adda
authors.forename: G
authors.initials: G
authors.lastname: Canavese
authors.forename: A
authors.initials: A
authors.lastname: Guariglia
authors.forename: D
authors.initials: D
authors.lastname: Santini
authors.forename: P
authors.initials: P
authors.lastname: Tomassetti
authors.forename: M L
authors.initials: ML
authors.lastname: Brandi
mesh_terms: D000328:Adult; D000483:Alleles; D002276:Carcinoid Tumor / Q000473:pathology; D002880:Chromosomes, Human, Pair 11; D004273:DNA, Neoplasm / Q000235:genetics; D004276:DNA, Satellite / Q000235:genetics; D018450:Disease Progression; D004379:Duodenal Neoplasms / Q000235:genetics / Q000473:pathology; D005260:Female; D015408:Gastrinoma / Q000235:genetics / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D018358:Neuroendocrine Tumors / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D016133:Polymerase Chain Reaction / Q000379:methods; D011379:Prognosis; D013274:Stomach Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*
chemical_list: D004273:DNA, Neoplasm; D004276:DNA, Satellite